Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19

Michael A. Thompson, View ORCID ProfileJeffrey P. Henderson, View ORCID ProfilePankil K. Shah, View ORCID ProfileSamuel M. Rubinstein, View ORCID ProfileMichael J. Joyner, View ORCID ProfileToni K. Choueiri, View ORCID ProfileDaniel B. Flora, View ORCID ProfileElizabeth A. Griffiths, Anthony P. Gulati, View ORCID ProfileClara Hwang, View ORCID ProfileVadim S. Koshkin, Esperanza B. Papadopoulos, Elizabeth V. Robilotti, View ORCID ProfileChristopher T. Su, View ORCID ProfileElizabeth M. Wulff-Burchfield, View ORCID ProfileZhuoer Xie, View ORCID ProfilePeter Paul Yu, View ORCID ProfileSanjay Mishra, View ORCID ProfileJonathon W. Senefeld, View ORCID ProfileDimpy P. Shah, View ORCID ProfileJeremy L. Warner
doi: https://doi.org/10.1101/2021.02.05.21250953
Michael A. Thompson
1Aurora Cancer Care, Advocate Aurora Health, Milwaukee, W
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey P. Henderson
2Washington University School of Medicine, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeffrey P. Henderson
Pankil K. Shah
3Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pankil K. Shah
Samuel M. Rubinstein
4University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel M. Rubinstein
Michael J. Joyner
5Mayo Clinic Cancer Center, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael J. Joyner
Toni K. Choueiri
6Dana-Farber Cancer Institute, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Toni K. Choueiri
Daniel B. Flora
7St. Elizabeth Healthcare, Edgewood, KY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniel B. Flora
Elizabeth A. Griffiths
8Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth A. Griffiths
Anthony P. Gulati
9Stamford Hospital, Stamford, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara Hwang
10Henry Ford Cancer Institute, Detroit, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Clara Hwang
Vadim S. Koshkin
11UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vadim S. Koshkin
Esperanza B. Papadopoulos
12Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth V. Robilotti
12Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher T. Su
13University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher T. Su
Elizabeth M. Wulff-Burchfield
14University of Kansas Medical Center, Kansas City, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth M. Wulff-Burchfield
Zhuoer Xie
5Mayo Clinic Cancer Center, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhuoer Xie
Peter Paul Yu
15Hartford Health Care, Farmington, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Paul Yu
Sanjay Mishra
16Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanjay Mishra
Jonathon W. Senefeld
5Mayo Clinic Cancer Center, Rochester, MN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathon W. Senefeld
Dimpy P. Shah
3Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dimpy P. Shah
Jeremy L. Warner
16Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeremy L. Warner
  • For correspondence: jeremy.warner@vumc.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Convalescent plasma may benefit immunocompromised individuals with COVID-19, including those with hematologic malignancy. We evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic malignancy and COVID-19 from a multi-institutional cohort. 143 treated patients were compared to 823 untreated controls. After adjustment for potential confounding factors, convalescent plasma treatment was associated with improved 30-day mortality (hazard ratio, 0.60; 95% CI, 0.37-0.97). This association remained significant after propensity-score matching (hazard ratio, 0.52; 95% CI, 0.29-0.92). These findings suggest a potential survival benefit in the administration of convalescent plasma to patients with hematologic malignancy and COVID-19.

Competing Interest Statement

Michael A. Thompson reports Travel support from Syapse, Royalties from UpToDate, Connect MDS/AML Registry in Celgene, Myeloma Registry in Takeda; Stock ownership in Doximity; personal fees from VIA Oncology, Adaptive Advisory Board, and GSK. Dr. Thompson is the Local PI for Clinical Trials in AbbVie, BMS, CRAB CTC, Denovo, Research Network, Eli Lilly, LynxBio, Strata Oncology, TG Therapeutics; all outside the submitted work. Jeffrey P. Henderson reports grant from the Longer Life Foundation: an RGA/Washington University Partnership; and unrestricted financial gift from Octapharma USA, Inc. to his institution to support COVID research in his laboratory during the conduct of the study. Pankil K. Shah reports grants from BARDA during the conduct of the study. Michael J. Joyner reports grants from BARDA during the conduct of the study. Toni K. Choueiri reports Honoraria from Alexion Pharmaceutic support; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; PER; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate; Consulting or Advisory Role from Alexion Pharmaceuticals; alligent; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; Ipsen; Kidney Cancer Association; Lancet Oncology; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate; Research Funding from Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst) all outside the submitted work. Elizabeth A. Griffiths reports honoraria for advisory boards from Alexion Pharmaceuticals, Celgene/Bristol-Myers Squibb, AbbVie, and Novartis; and institutional research funding from Astex/Otsuka, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Celgene/Bristol-Myers Squibb, Celldex Therapeutics, and Genentech. Vadim S. Koshkin reports personal fees from Pfizer, Janssen, Dendrreon, AstraZeneca, Seattle Genetics, Clovis; grants from Nektar, Novartis / Endocyte, Janssen, Clovis, Prostate Cancer Foundation; all outside the submitted work. Elizabeth Wulff-Burchfield reports personal fees from Astellas, Bristol Myers Squibb (BMS); grants from Pfizer Global Medical Grants; Advisory board membership in Exelixis; stock ownership by a family member in Nektar and Immunomedics; all outside the submitted work. Dimpy P. Shah reports grants from BARDA, the American Cancer Society and Hope Foundation for Cancer Research during the conduct of the study. Jeremy L. Warner reports grants from National Cancer Institute, during the conduct of the study; personal fees from Westat, IBM Watson Health, and HemOnc.org LLC; all outside the submitted work. Samuel Rubinstein, Daniel Flora, Anthony P. Gulati, Clara Hwang, Esperanza B. Papadopoulos, Elizabeth V. Robilotti, Christopher T. Su, Zhuoer Xie, Peter Paul Yu, Sanjay Mishra, and Jonathon W. Senefeld have nothing to disclose.

Clinical Trial

NCT04354701

Funding Statement

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority under Contract No. 75A50120C00096; National Cancer Institute (NCI) grants P30 CA008748, P30 CA046592, P30 CA054174, P30 CA068485, T32 CA236621, and U01 CA231840; National Center for Advancing Translational Sciences (NCATS) grant UL1 TR002377; Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors); United Health Group; National Basketball Association (NBA); Millennium Pharmaceuticals; Octapharma USA, Inc; the American Cancer Society and Hope Foundation for Cancer Research grant MRSG-16-152-01-CCE; the Longer Life Foundation: A RGA/Washington University Partnership; and the Mayo Clinic. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB exemption was determined by the Vanderbilt University IRB, #200467

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The full CCC19 data dictionary and R code to generate the derived variables is publicly available on GitHub. The data used for the analyses will be made available in aggregate form through a dashboard on the ccc19.org website, six months from the peer-reviewed publication of this research.

https://github.com/covidncancer/CCC19_dictionary

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 05, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
Michael A. Thompson, Jeffrey P. Henderson, Pankil K. Shah, Samuel M. Rubinstein, Michael J. Joyner, Toni K. Choueiri, Daniel B. Flora, Elizabeth A. Griffiths, Anthony P. Gulati, Clara Hwang, Vadim S. Koshkin, Esperanza B. Papadopoulos, Elizabeth V. Robilotti, Christopher T. Su, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Peter Paul Yu, Sanjay Mishra, Jonathon W. Senefeld, Dimpy P. Shah, Jeremy L. Warner
medRxiv 2021.02.05.21250953; doi: https://doi.org/10.1101/2021.02.05.21250953
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19
Michael A. Thompson, Jeffrey P. Henderson, Pankil K. Shah, Samuel M. Rubinstein, Michael J. Joyner, Toni K. Choueiri, Daniel B. Flora, Elizabeth A. Griffiths, Anthony P. Gulati, Clara Hwang, Vadim S. Koshkin, Esperanza B. Papadopoulos, Elizabeth V. Robilotti, Christopher T. Su, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Peter Paul Yu, Sanjay Mishra, Jonathon W. Senefeld, Dimpy P. Shah, Jeremy L. Warner
medRxiv 2021.02.05.21250953; doi: https://doi.org/10.1101/2021.02.05.21250953

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (455)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (159)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5294)
  • Forensic Medicine (3)
  • Gastroenterology (198)
  • Genetic and Genomic Medicine (760)
  • Geriatric Medicine (80)
  • Health Economics (214)
  • Health Informatics (702)
  • Health Policy (362)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (165)
  • Infectious Diseases (except HIV/AIDS) (5934)
  • Intensive Care and Critical Care Medicine (367)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (772)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (153)
  • Orthopedics (39)
  • Otolaryngology (97)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2035)
  • Radiology and Imaging (354)
  • Rehabilitation Medicine and Physical Therapy (159)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)